SG161242A1 - Rage fusion proteins and methods of use - Google Patents

Rage fusion proteins and methods of use

Info

Publication number
SG161242A1
SG161242A1 SG201002393-5A SG2010023935A SG161242A1 SG 161242 A1 SG161242 A1 SG 161242A1 SG 2010023935 A SG2010023935 A SG 2010023935A SG 161242 A1 SG161242 A1 SG 161242A1
Authority
SG
Singapore
Prior art keywords
rage
fusion proteins
methods
rage fusion
disclosed
Prior art date
Application number
SG201002393-5A
Other languages
English (en)
Inventor
Adnan M M Mjalli
David M Stern
Ye E Tian
Jeffrey C Webster
Robert Rothlein
Ann Marie Schmidt
Shi Du Yan
Original Assignee
Transtech Pharma Inc
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG161242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transtech Pharma Inc, Univ Columbia filed Critical Transtech Pharma Inc
Publication of SG161242A1 publication Critical patent/SG161242A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
SG201002393-5A 2004-08-03 2005-08-03 Rage fusion proteins and methods of use SG161242A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59836204P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
SG161242A1 true SG161242A1 (en) 2010-05-27

Family

ID=35427536

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002393-5A SG161242A1 (en) 2004-08-03 2005-08-03 Rage fusion proteins and methods of use

Country Status (23)

Country Link
US (2) US20090060925A1 (fr)
EP (1) EP1776459A1 (fr)
JP (1) JP2008508882A (fr)
KR (1) KR20070057818A (fr)
CN (1) CN101010430A (fr)
AP (1) AP2007003893A0 (fr)
AU (2) AU2005271449A1 (fr)
BR (1) BRPI0514013A (fr)
CA (1) CA2575830A1 (fr)
CR (2) CR8897A (fr)
EA (1) EA012586B1 (fr)
EC (1) ECSP077297A (fr)
GE (1) GEP20105111B (fr)
IL (1) IL180555A0 (fr)
MA (1) MA28781B1 (fr)
MX (1) MX2007001556A (fr)
NO (1) NO20070062L (fr)
NZ (1) NZ552842A (fr)
SG (1) SG161242A1 (fr)
TN (1) TNSN07040A1 (fr)
UA (1) UA92154C2 (fr)
WO (1) WO2006017643A1 (fr)
ZA (1) ZA200700641B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
EP1121454B1 (fr) * 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Nouvelle proteine extracellulaire liant le peptide rage (en-rage), et utilisations correspondantes
WO2002030889A2 (fr) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York Methode pour inhiber une nouvelle croissance tissulaire dans les vaisseaux sanguins d'un patient presentant une lesion
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1771565B1 (fr) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Derives de proteine rage
NZ552842A (en) * 2004-08-03 2010-05-28 Univ Columbia Rage fusion proteins and methods of use
ES2473587T3 (es) * 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006099620A2 (fr) * 2005-03-17 2006-09-21 The Trustees Of Columbia University In The City Of New York Interaction rage/diaphane et compositions et methodes associees
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
RU2431804C2 (ru) * 2005-12-23 2011-10-20 ДжиКоудер Системз АБ Шаблон позиционирования
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US7981424B2 (en) * 2006-05-05 2011-07-19 Transtech Pharma, Inc. RAGE fusion proteins, formulations, and methods of use thereof
EP2450372B1 (fr) 2007-01-30 2015-04-22 Epivax, Inc. Épitopes de lymphocytes T régulateurs, compositions et utilisations de ceux-ci
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
WO2008153957A1 (fr) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Utilisation d'antagonistes de rage pour le traitement de l'obésité et de maladies associées
KR101595634B1 (ko) * 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
WO2013103688A1 (fr) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs humains solubles pour produits finaux de glycation avancée (srage), procédé de préparation de srage humain et traitement et procédés utilisant un srage
CN103376328A (zh) * 2013-07-18 2013-10-30 上海交通大学医学院附属瑞金医院 血清sRAGE水平的检测试剂在筛选改善胰岛素β细胞功能的糖尿病治疗药物中的应用
KR101645654B1 (ko) * 2014-05-02 2016-08-05 서울대학교산학협력단 Rage로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 뇌혈관질환의 예방 또는 치료용 약학적 조성물
CA3112637A1 (fr) 2018-09-14 2020-03-19 BioAge Labs, Inc. Proteines de fusion rage presentant une stabilite et une affinite de liaison aux ligands ameliorees et leurs utilisations
JP7477141B2 (ja) * 2019-02-21 2024-05-01 国立研究開発法人農業・食品産業技術総合研究機構 肝疾患診断技術
JP7479039B2 (ja) * 2019-02-21 2024-05-08 国立研究開発法人農業・食品産業技術総合研究機構 糖尿病診断技術

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) * 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5891341A (en) * 1995-04-05 1999-04-06 The Picower Institute For Medical Research Compositions and devices for partitioning advanced glycosylation endproducts, and methods of their use
PT808163E (pt) * 1995-01-18 2003-12-31 Alteon Inc Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
EP1121454B1 (fr) * 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Nouvelle proteine extracellulaire liant le peptide rage (en-rage), et utilisations correspondantes
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
EP1252305A2 (fr) * 1999-12-08 2002-10-30 Genset Adnc humains pleine longueur codant pour des proteines potentiellement secretees
EP1272843B1 (fr) * 2000-04-14 2007-06-20 Niadyne Corporation Procede d'identification de regulateurs de la formation de produits finaux de glycation a avancement proteique
US7087632B2 (en) * 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6900041B2 (en) * 2000-10-02 2005-05-31 Reddy Us Therapeutics Inc. Methods and compositions for the treatment of inflammatory diseases
WO2002030889A2 (fr) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York Methode pour inhiber une nouvelle croissance tissulaire dans les vaisseaux sanguins d'un patient presentant une lesion
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
HUP0600450A2 (en) * 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
EP1361891A2 (fr) * 2001-02-19 2003-11-19 MERCK PATENT GmbH Proteines artificielles presentant une immunogenicite reduite
EP1377295A4 (fr) * 2001-03-05 2007-05-09 Transtech Pharma Inc Derives de carboxamide utilises comme agents therapeutiques
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US6861888B2 (en) * 2002-01-16 2005-03-01 Agilent Technologies, Inc. High-sensitivity differential data latch system
WO2003075921A2 (fr) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Derives de l'azole et derives bicycliques fusionnes de l'azole, agents therapeutiques
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
WO2005021710A2 (fr) * 2003-06-02 2005-03-10 University Of Miami Molecules chimeres et procedes d'utilisation correspondants
US6969545B2 (en) * 2003-07-28 2005-11-29 Deere & Company Hydrogen storage container
WO2005023191A2 (fr) * 2003-09-05 2005-03-17 The Trustees Of Columbia University In The City Of New York Procedes et compositions associes aux produits terminaux de la glycation avancee pour le traitement de la lesion glomerulaire
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
WO2005042782A1 (fr) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methodes permettant de limiter un dommage neuronal induit par une crise epileptique
EP1771565B1 (fr) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Derives de proteine rage
ES2473587T3 (es) * 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
NZ552842A (en) * 2004-08-03 2010-05-28 Univ Columbia Rage fusion proteins and methods of use
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006099620A2 (fr) * 2005-03-17 2006-09-21 The Trustees Of Columbia University In The City Of New York Interaction rage/diaphane et compositions et methodes associees
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US7981424B2 (en) * 2006-05-05 2011-07-19 Transtech Pharma, Inc. RAGE fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
WO2008153957A1 (fr) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Utilisation d'antagonistes de rage pour le traitement de l'obésité et de maladies associées
US9491184B2 (en) * 2008-04-04 2016-11-08 Samsung Electronics Co., Ltd. Method and apparatus for managing tokens for digital rights management

Also Published As

Publication number Publication date
IL180555A0 (en) 2007-06-03
ZA200700641B (en) 2008-10-29
NZ552842A (en) 2010-05-28
CR8897A (es) 2007-06-29
CA2575830A1 (fr) 2006-02-16
AU2005271449A1 (en) 2006-02-16
TNSN07040A1 (fr) 2008-06-02
NO20070062L (no) 2007-01-31
BRPI0514013A (pt) 2008-05-27
AP2007003893A0 (en) 2007-02-28
EA012586B1 (ru) 2009-10-30
ECSP077297A (es) 2007-05-30
CN101010430A (zh) 2007-08-01
MA28781B1 (fr) 2007-08-01
GEP20105111B (en) 2010-11-10
JP2008508882A (ja) 2008-03-27
AU2010201531A1 (en) 2010-05-06
MX2007001556A (es) 2008-03-05
EP1776459A1 (fr) 2007-04-25
EA200700402A1 (ru) 2007-08-31
KR20070057818A (ko) 2007-06-07
US20090060925A1 (en) 2009-03-05
CR20110557A (es) 2011-12-05
US20060078562A1 (en) 2006-04-13
UA92154C2 (ru) 2010-10-11
WO2006017643A1 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
SG161242A1 (en) Rage fusion proteins and methods of use
UA93356C2 (ru) Белки слияния ha ochobe rage и способы их использования
WO2007094926A3 (fr) Protéines hybrides rage et leurs procédés d'utilisation
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
EP3670534A3 (fr) Récepteur fgf humain et protéines de liaison de bêta-klotho
ECSP067073A (es) Anticuerpos anti-il-13 y complejos
WO2006110292A3 (fr) Immobilisation et purification d'anticorps declenchees par la temperature
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
EA200800696A1 (ru) Полипептиды и антитела
MX341148B (es) PROTEINAS DE ENLACE A ANTIGENOS HUMANAS QUE ENLAZAN ß-KLOTHO, RECEPTORES FGF Y COMPLEJOS DE LOS MISMOS.
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
ZA200800104B (en) Novel Phage Display Technologies
GB0226729D0 (en) Intracellular antibodies
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
AU2003266135A1 (en) Method of visualizing proteins bound to protein-binding membranes
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
CU23703A3 (es) Proteínas de fusión rage y métodos de uso
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
WO2005051994A3 (fr) Facteur de necrose tumorale ztnf11
WO2005058952A3 (fr) Ztnf13, facteur de necrose tumorale
TR201909281T4 (tr) HER-3'e yönelik antikorlar ve bunların kullanımı.